FDA approves low-dose rivaroxaban for long-term PE/DVT prevention
www.pulmccm.org
The long-term management of recurrent venous thromboembolism continues to evolve with the FDA's approval of once-daily low-dose rivaroxaban, now indicated for patients with recurrent deep venous thrombosis or pulmonary embolism who have completed at least six months of anticoagulation.
FDA approves low-dose rivaroxaban for long-term PE/DVT prevention
FDA approves low-dose rivaroxaban for…
FDA approves low-dose rivaroxaban for long-term PE/DVT prevention
The long-term management of recurrent venous thromboembolism continues to evolve with the FDA's approval of once-daily low-dose rivaroxaban, now indicated for patients with recurrent deep venous thrombosis or pulmonary embolism who have completed at least six months of anticoagulation.